Maqola mavzusi

Mualliflar

Ibrohimova L.I., Kambarova L.SH., Ergasheva Z.O.

Muassasa

Tashkent State Medical University, Tashkent, Uzbekistan

Annotatsiya

According to the International Diabetes Federation (IDF), 589 million adults (aged 20–79) have diabetes; this number is expected to reach 853 million by 2050. Incidence: The prevalence of diabetes in adults doubled between 1990 and 2022 (from 7% to 14%), largely driven by unfavourable factors in low- and middle-income countries. Regional differences: The greatest increases and lowest treatment coverage are observed in Southeast Asia, the Eastern Mediterranean and Africa. Main types: Type 2 diabetes accounts for 90–96% of all cases and is often associated with lifestyle. The social significance of diabetes lies in its capacity to cause premature disability and mortality, primarily through vascular complications associated with microangiopathy and macroangiopathy. In addition, the progressive rise in healthcare expenditures linked to diabetes management imposes a substantial economic burden on health systems worldwide. These realities highlight the urgent need for innovative measures aimed at reducing both the prevalence of diabetes and its associated complications. Within this context, experimental diabetology plays a pivotal role in advancing knowledge of the pathogenesis, clinical manifestations, therapeutic approaches, and preventive strategies for the disease

Kalit so'zlar

diabetes mellitus,white laboratory rats, alloxan diabetes, thoracic cage

Adabiyotlar